CI

At a glance

ClinicalIndex Comparison Record
N/AUnknown· 120 enrolled
Drug / intervention
Ramelteon +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02691013
NCT02691013N/AUnknown

The Impact of Ramelteon on Sleep and Delirium in Patients Who Undergo Pulmonary Thromboendarterectomy (PTE) Surgery

University of California, San Diego·interventional·Posted Feb 24, 2016·Updated Feb 8, 2022

In Brief

A clinical study evaluating Ramelteon and Placebo for Delirium and Sleep Deprivation. Targeting 120 participants.

Detailed Summary

Sleep deprivation is known to affect brain function but is often ignored in the sickest patients including those in the intensive care unit after major surgery. In these patients, the levels of melatonin can also be altered. Melatonin is a hormone secreted in the brain that maintains the body's sleep-wake, or circadian, cycle. The investigators want to test whether improving sleep quality affects the risk of developing confusion (delirium) in patients having clot removed from their lung (open heart surgery). In order to improve sleep quality, the investigators will conduct a study of Ramelteon, a medication that mimics the activity of melatonin and measure its effects on levels of melatonin and monitor sleep.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

N/AUnknownOverdue
20162017201820192020202120222023202420252026
First PostedFeb 24, 2016
Enrollment StartFeb 1, 2016
Primary CompletionDec 31, 2017
Study CompletionDec 1, 2022
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 10.4 years ago

Interventions

Ramelteondrug

Placebodrug